Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy

被引：0

作者：

Jiang, Mengshi ^{[1
]}

Li, Wei ^{[2
]}

Zhu, Chunqi ^{[1
]}

Li, Xiang ^{[1
]}

Zhang, Junlei ^{[1
]}

Luo, Zhenyu ^{[1
]}

Qin, Bing ^{[1
]}

Du, Yongzhong ^{[1
]}

Luo, Lihua ^{[1
]}

You, Jian ^{[1
]}

机构：

[1] College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou,Zhejiang,310058, China

[2] Department of Pharmacology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas,TX,75390, United States

来源：

Journal of Controlled Release | 2021年 / 329卷

基金：

中国国家自然科学基金;

关键词：

Targeted drug delivery - Hyaluronic acid - Cancer cells - Cytology - Micelles - Diseases - Drug interactions - Tumors - Controlled drug delivery - Covalent bonds - Immune system - Pathology - Sulfur compounds - Drug dosage - Cells;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1023 / 1036

共 50 条

[31] GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity
Capello, Michela
Sette, Angelica
Plantinga, Theo
Spires, Vanessa
Nuermberger, Kristina
Blum, Jordan
Muik, Alexander
Sa, Carol Costa
Jabado, Omar
Burm, Saskia
Toker, Aras
Fellermeier-Kopf, Sina
Ahmadi, Tahi
Higgs, Brandon
Couto, Suzana
Tureci, Ozlem
Fereshteh, Mark
Sahin, Ugur
Jure-Kunkel, Maria
Pencheva, Nora
CANCER RESEARCH, 2023, 83 (07)
[32] Enhancement of anti-tumor effects of PD-1 inhibitors by modulation of lipid metabolism in tumor microenvironment
Katoh, Yuki
Yaguchi, Tomonori
Iwata, Takashi
Kawana, Kei
Kawakami, Yutaka
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2021, 148 : 1 - 2
[33] Talilmogene laherparepvec increases the anti-tumor efficacy of the anti PD-1 immune checkpoint blockade
Piasecki, Julia
Le, Tiep
Ponce, Rafael
Beers, Courtney
CANCER RESEARCH, 2015, 75
[34] Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity
Jiawei Yue
Hui Guo
Peng Xu
Jinhong Ma
Weifeng Shi
Yumin Wu
Cancer Immunology, Immunotherapy, 73
[35] Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity
Yue, Jiawei
Guo, Hui
Xu, Peng
Ma, Jinhong
Shi, Weifeng
Wu, Yumin
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (04)
[36] D-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity
Dong, Wenjing
Lin, Mingen
Zhang, Ruonan
Sun, Xue
Li, Hongchen
Liu, Tianshu
Xu, Yanping
Lv, Lei
CANCER LETTERS, 2024, 591
[37] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
Albu, Diana I.
Wolf, Benjamin J.
Qin, Yan
Wang, Xianzhe
Ulumben, Amy Daniel
Su, Mei
Li, Vivian
Ding, Eirene
Gonzalo, Jose Angel
Kong, Jason
Jadhav, Ruturaj
Kuklin, Nelly
Visintin, Alberto
Gong, Bing
Schuetz, Thomas J.
ONCOIMMUNOLOGY, 2024, 13 (01):
[38] Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade
Jin, Chengyan
Zhang, Yan
Li, Baofeng
Gao, Tianci
Wang, Bin
Hua, Peiyan
MATERIALS TODAY BIO, 2024, 27
[39] PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
Zahm, Christopher D.
Moseman, Jena E.
Delmastro, Lauren E.
G. Mcneel, Douglas
ONCOIMMUNOLOGY, 2021, 10 (01):
[40] Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
Shin, Jae Hun
Park, Hyung Bae
Choi, Kyungho
IMMUNE NETWORK, 2016, 16 (02) : 134 - 139

← 1 2 3 4 5 →